KCS Wealth Advisory bought a new position in shares of GlaxoSmithKline plc (NYSE:GSK) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,009 shares of the pharmaceutical company’s stock, valued at approximately $461,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FinTrust Investment Advisory Services LLC purchased a new position in GlaxoSmithKline in the third quarter valued at $401,000. Private Advisor Group LLC boosted its holdings in GlaxoSmithKline by 7.2% in the third quarter. Private Advisor Group LLC now owns 77,976 shares of the pharmaceutical company’s stock valued at $3,166,000 after purchasing an additional 5,212 shares during the period. San Francisco Sentry Investment Group CA boosted its holdings in GlaxoSmithKline by 110.3% in the third quarter. San Francisco Sentry Investment Group CA now owns 8,749 shares of the pharmaceutical company’s stock valued at $356,000 after purchasing an additional 4,589 shares during the period. Renaissance Technologies LLC boosted its holdings in GlaxoSmithKline by 112.1% in the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock valued at $402,655,000 after purchasing an additional 4,935,900 shares during the period. Finally, SG Americas Securities LLC purchased a new position in GlaxoSmithKline in the third quarter valued at $1,209,000. Institutional investors and hedge funds own 9.70% of the company’s stock.
A number of analysts have issued reports on the company. UBS Group raised GlaxoSmithKline from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $35.04 to $35.85 in a report on Monday, November 27th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, January 29th. Cowen set a $38.00 price target on GlaxoSmithKline and gave the stock a “hold” rating in a report on Monday, December 11th. ValuEngine downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Barclays raised GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 16th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $38.57.
In other news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were acquired at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 10.00% of the stock is currently owned by insiders.
GlaxoSmithKline plc (NYSE GSK) traded down $0.49 on Friday, hitting $37.10. The stock had a trading volume of 3,343,786 shares, compared to its average volume of 4,617,797. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44. GlaxoSmithKline plc has a twelve month low of $34.52 and a twelve month high of $44.53. The firm has a market capitalization of $91,969.94, a PE ratio of 30.41, a P/E/G ratio of 2.30 and a beta of 0.98.
TRADEMARK VIOLATION WARNING: “KCS Wealth Advisory Invests $461,000 in GlaxoSmithKline plc (GSK) Stock” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/04/13009-shares-in-glaxosmithkline-plc-gsk-acquired-by-kcs-wealth-advisory.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.